On July 23, Elevance Health rose 3.06% overnight, trading at $401.0/share, with turnover of $332,400. The stock continues its recovery trajectory following the Q2 earnings release on July 15, during which shares initially plunged over 10% due to Medicaid utilization pressure and operating margin contraction.

The rebound is supported by multiple investment banks raising price targets in rapid succession: Wells Fargo to $492, Truist to $475, and Guggenheim to $455. Truist lifted its EPS estimate to $27.12 for the current fiscal year and $29.14 for the following year, citing the strong Q2 beat and elevated guidance as foundations for long-term improvement. The FactSet consensus target stands at $445.57, implying significant upside from current levels.

The Q2 report showed adjusted EPS of $7.45, beating the $6.21 consensus by approximately 20%, while revenue of $49.83 billion also exceeded expectations. The company raised full-year adjusted EPS guidance to at least $27. However, operating margin declined to 3.5% from 4.9% year-over-year, and the CEO indicated plans to exit additional Medicaid markets over the next 12 to 18 months.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)